About
The Innate Immunity group has been active since 2009 and is focussed on the study of Innate Immunity in health and disease. It is located in the IGTP, Can Ruti Campus, and it is part of the CIBERehd Consortium of the Spanish Government (ISCIII) and the AGAUR Research Quality Group 2017-SGR-490. We are conducting research on three important aspects of human pathology: liver disease, atherosclerosis and bacterial infection.
Our aim is to define the role of Innate Immunity proteins as prognostic or diagnostic biomarkers of disease. We also aim at generating knowledge for the development of new pharmacological agents that modulate Innate Immune responses. In this context, our interests are at present mostly centred on the role of macrophage protein CD5L in the control of immune homeostasis and inflammatory disease.
Research lines
Role of Innate Immunity in liver disease
Our main objective is to study microenvironment interactions in the setting of liver disease. Our functional studies are focussed on the intercommunication between two key liver cell types, macrophages and hepatic stellate cells, with hepatocytes. With a more clinically oriented goal, we are exploring the potential of several Innate Immunity proteins as biomarkers for the improvement of patient management. Both approaches will lead to a better understanding of the complex mechanisms underlying liver disease.
This work has been funded by grants from ISCIII- ERDF (FIS PI13/1906, Miguel Servet CPII/14/0021, Juan de la Cierva, FJCI-2014-20505), and La Marató de TV3 Foundation (MTV3-20133610).
Role of CD5L and CD36 in the physiology of macrophages in atherosclerosis
Under persistent hyperlipidemic conditions, a series of changes in the vessel wall may lead to atherosclerosis, a chronic inflammatory condition in which macrophages play a key role. Complications of atherosclerosis such as plaque rupture and thrombosis are the most common causes of death in Western societies. Our purpose is to determine the contribution of CD5L and its cellular receptor CD36 to key events of macrophage physiology in the context of atherosclerosis.
This work has been funded by grants from La Marató de TV3 Foundation (MTV3 080932), and the European Foundation for the Study of Diabetes (EFSD).
Role of CD5L in bacterial infection
The Innate Immune response is the first line of defence against invading pathogens. We are devoted to understand the complex interplay between host defence and pathogen evasion. Our studies include the role of CD5L in modulating macrophage responses to bacterial products, from inflammatory molecules (eg LPS) to whole organisms, such as Escherichia coli or Mycobacterium tuberculosis. This line of research opens the door to the discovery of new therapeutic targets.
This work has been funded by ISCIII-ERDF (FIS IP10/1656, and Miguel Servet CP08/124).
Projects
Ongoing Projects
Novel cancer immunotherapy strategy and companion diagnostic
Code: 2019PROD00118
Principal Investigator Maria-Rosa Sarrias
Start Date: 01/01/2017
End Date: 21/07/2020
Perfil fenotípico-funcional del macrófago en cirrosis y cáncer hepatocelular y su manifestación en plasma: nueva oportunidad pronóstico-terapéutica
Code: PI16/00974
Principal Investigator Maria-Rosa Sarrias
Start Date: 01/01/2017
End Date: 31/12/2019
New in Vitro Diagnostic devices for the clinical management of tuberculosis and hepatocellular carcinoma
Code: 2016 PRODUCTE 0094
Principal Investigator Maria-Rosa Sarrias
Start Date: 01/08/2017
End Date: 31/01/2019
Grup de recerca translacional en patologia hepàtica i immunitat innata
Code: 2017-SGR 490
Principal Investigator Carolina Armengol
Start Date: 01/01/2017
End Date: 31/12/2019
Children's Liver Tumour European Research Network
Code Grant Agreement: 668596
Principal Investigator K Wheatley (WP3 Leader: C Armengol, IGTP)
Start Date: 01/01/2016
End Date: 31/12/202
News
Nueva inmunoterapia dirigida a macrófagos tumorales para abordar el cáncer de pulmón
Investigadores del grupo de Inmunidad Innata del Instituto de Investigación Germans Trias i Pujol (IGTP) han desarrollado una nueva inmunoterapia basada en un anticuerpo monoclonal dirigido contra macrófagos tumorales. Los resultados obtenidos establecen las bases de un nuevo tratamiento para pacientes con cáncer de pulmón, con el potencial de aplicarse en otros tumores sólidos. El estudio se ha publicado en la revista eBioMedicine.
Un proyecto que desarrolla una nueva inmunoterapia basada en un anticuerpo monoclonal para el tratamiento contra el cáncer entre las tres iniciativas seleccionadas por CaixaResearch Consolidate
El proyecto de un anticuerpo monoclonal para el tratamiento contra el cáncer, liderado desde el grupo de investigación de Inmunidad Innata del IGTP, es uno de los tres seleccionados en la convocatoria del programa CaixaResearch Consolidatede de la Fundación “la Caixa” que otorga ayudas a proyectos de innovación biomédica puntera.
Contact
Maria-Rosa Sarrias, Group Leader
(+34) 93 554 3060